| Nov 20 |
Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference
|
| Nov 14 |
Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Oct 9 |
Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit
|
| Oct 1 |
Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies
|
| Sep 24 |
Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer
|
| Sep 11 |
Why Dave & Buster's Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
|
| Sep 9 |
PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers
|
| Sep 3 |
Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference
|
| Aug 15 |
Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination
|
